A narrative review looked at how antibodies targeting the TNF–TNFR2 axis might help treat cancer. This type of review discusses existing research rather than presenting new data from a single trial. The intervention includes monoclonal antibodies, antibody–drug conjugates, and bispecific antibodies. The review notes that these approaches are being explored as potential treatments for cancer patients.
The authors highlight several important limitations that affect how we should view these findings. First, there is a risk of on-target toxicity, meaning the treatment might affect healthy cells. Second, patient stratification is unclear, so it is not yet known which specific patients might benefit most. Third, the biology of TNFR2 can change depending on the context, which adds complexity to the science.
Because this is a narrative review, it does not provide definitive proof of effectiveness or safety. The study did not report specific adverse events, serious adverse events, discontinuations, or tolerability data. Readers should understand that this information is preliminary. More rigorous studies are required to confirm benefits and risks before these therapies become standard care.